FHD-286 is a small molecule commercialized by Foghorn Therapeutics, with a leading Phase I program in Chronic Myelomonocytic Leukemia (CMML). According to Globaldata, it is involved in 2 clinical trials, of which 1 is ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of FHD-286’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for FHD-286 is expected to reach an annual total of $74 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
FHD-286 Overview
Foghorn Therapeutics Overview
Foghorn Therapeutics is a pharmaceutical company. The company discovers and develops novel drugs to treat cancer and other serious medical disorders. Its Gene Traffic Control Platform is a chromatin regulatory system that directs which genes our cells express and when, where and in what order. Foghorn Therapeutics products pipeline includes FHD-286 (BRM / BRG1), FHD-609 (BRD9), Selective BRM, and ARID1B. The company has developed a new approach of controlling gene expression, new insights, advanced six programs and created a discovery engine that yield’s additional targets in multiple types of cancers and other diseases. Foghorn Therapeutics is headquartered in Cambridge, Massachusetts, the US.
The company reported revenues of (US Dollars) US$34.2 million for the fiscal year ended December 2023 (FY2023), an increase of 77.6% over FY2022. The operating loss of the company was US$107.9 million in FY2023, compared to an operating loss of US$117.1 million in FY2022. The net loss of the company was US$98.4 million in FY2023, compared to a net loss of US$108.9 million in FY2022.
For a complete picture of FHD-286’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
